3-oxoindan-1-carbonyl chloride | 128478-07-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 3-oxoindan-1-carbonyl chloride
• 英文别名: 3-oxo-1,2-dihydroindene-1-carbonyl chloride
• CAS: 128478-07-9
• 化学式: C₁₀H₇ClO₂
• 分子量: 194.617
• InChiKey: UABLMMNFDCFQGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-oxoindan-1-carbonyl chloride 在 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 4-(4-methylpiperazin-1-yl)-N-[5-(3-oxo-1,2-dihydroindene-1-carbonyl)-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]benzamide
  参考文献：
  名称：

  The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing

  摘要：

  New drugs for neglected tropical diseases such as human African trypanosomiasis (HAT) are needed, yet drug discovery efforts are not often focused on this area due to cost. Target repurposing, achieved by the matching of essential parasite enzymes to those human enzymes that have been successfully inhibited by small molecule drugs, provides an attractive means by which new drug optimization programs can be pragmatically initiated. In this report we describe our results in repurposing an established class of human Aurora kinase inhibitors, typified by danusertib (1), which we have observed to be an inhibitor of trypanosomal Aurora kinase 1 (TbAUK1) and effective in parasite killing in vitro. Informed by homology modeling and docking, a series of analogs of I were prepared that explored the scope of the chemotype and provided a nearly 25-fold improvement in cellular selectivity for parasite cells over human cells. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.07.038
• 作为产物：
  描述：

  3-羰基-1-茚酸 在 草酰氯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 3-oxoindan-1-carbonyl chloride
  参考文献：
  名称：

  The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing

  摘要：

  New drugs for neglected tropical diseases such as human African trypanosomiasis (HAT) are needed, yet drug discovery efforts are not often focused on this area due to cost. Target repurposing, achieved by the matching of essential parasite enzymes to those human enzymes that have been successfully inhibited by small molecule drugs, provides an attractive means by which new drug optimization programs can be pragmatically initiated. In this report we describe our results in repurposing an established class of human Aurora kinase inhibitors, typified by danusertib (1), which we have observed to be an inhibitor of trypanosomal Aurora kinase 1 (TbAUK1) and effective in parasite killing in vitro. Informed by homology modeling and docking, a series of analogs of I were prepared that explored the scope of the chemotype and provided a nearly 25-fold improvement in cellular selectivity for parasite cells over human cells. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.07.038

文献信息

• Analgesic thiomorpholins their preparation, and pharmaceutical
  申请人：Sankyo Company Limited

  公开号：US05021413A1

  公开（公告）日：1991-06-04

  Analgesic compounds are of the general formula (I): ##STR1## in which, R.sup.1 and R.sup.2 each represents hydrogen or C.sub.1 -C.sub.6 alkyl, or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a heterocycle; E represents methylene, sulfur, oxygen or imino group optionally substituted with C.sub.1 -C.sub.6 alkyl or aralkyl; ring A is aryl or heteroaryl ring, optionally substituted; R.sup.3 is hydrogen or C.sub.1 -C.sub.6 alkyl and R.sup.4 is hydrogen or R.sup.3 and R.sup.4 together represent a group of formula (IV): --(CR.sup.a R.sup.a).sub.m --C(.dbd.Y)-- (IV) (wherein R.sup.a and R.sup.a is C.sub.1 -C.sub.6 alkyl or hydrogen, up to a maximum of 3 alkyl groups, m is 1, 2, or 3, and Y is two hydrogens or oxygen); provided that when E represents a methylene group, then R.sup.3 is a C.sub.1 -C.sub.6 alkyl group or R.sup.3 and R.sup.4 together represent a group of the formula (IV).

  镇痛化合物的一般式为（I）：##STR1## 在其中，R.sup.1和R.sup.2分别代表氢或C.sub.1-C.sub.6烷基，或者R.sup.1和R.sup.2与它们连接的氮原子一起形成杂环；E代表亚甲基、硫、氧或亚胺基，可选择地用C.sub.1-C.sub.6烷基或芳基取代；环A是芳基或杂芳基环，可选择地取代；R.sup.3是氢或C.sub.1-C.sub.6烷基，R.sup.4是氢或R.sup.3和R.sup.4一起代表式（IV）的基团：--(CR.sup.aR.sup.a).sub.m--C(.dbd.Y)--（IV）（其中R.sup.a和R.sup.a是C.sub.1-C.sub.6烷基或氢，最多有3个烷基基团，m为1、2或3，Y为两个氢或氧）；但是当E代表亚甲基时，R.sup.3是C.sub.1-C.sub.6烷基基团或R.sup.3和R.sup.4一起代表式（IV）的基团。
• Process for preparing analgesic compounds
  申请人：Sankyo Company, Limited

  公开号：US05656758A1

  公开（公告）日：1997-08-12

  A process for preparing a compound of the formula (I): ##STR1## in which, R.sup.1 and R.sup.2 each represents hydrogen or C.sub.1 -C.sub.6 alkyl, or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a heterocycle; E represents methylene, sulfur, oxygen or imino group optionally substituted with C.sub.1 -C.sub.6 alkyl or aralkyl; ring A is aryl or heteroaryl ring, optionally substituted; R.sup.3 is hydrogen or C.sub.1 -C.sub.6 alkyl and R.sup.4 is hydrogen or R.sup.3 and R.sup.4 together represent a group of formula (IV): --(CR.sup.a R.sup.a).sub.m --C(.dbd.Y)-- (IV) (wherein R.sup.a and R.sup.a is C.sub.1 -C.sub.6 alkyl or hydrogen, up to a maximum of 3 alkyl groups, m is 1, 2, or 3, and Y is two hydrogens or oxygen); provided that when E represents a methylene group, then R.sup.3 is a C.sub.1 -C.sub.6 alkyl group or R.sup.3 and R.sup.4 together represent a group of the formula (IV), which comprises reacting an acid of the formula ##STR2## with an amine of the formula ##STR3##

  一种制备化合物(I)的方法：其中，R.sup.1和R.sup.2分别表示氢或C.sub.1-C.sub.6烷基，或者R.sup.1和R.sup.2与它们所连接的氮原子形成杂环；E表示亚甲基、硫、氧或亚胺基，可选地被C.sub.1-C.sub.6烷基或芳基烷基取代；环A是芳基或杂芳基环，可选地被取代；R.sup.3是氢或C.sub.1-C.sub.6烷基，R.sup.4是氢或R.sup.3和R.sup.4共同表示式(IV)的一个组，其中，--(CR.sup.aR.sup.a).sub.m--C(.dbd.Y)--(IV)（其中，R.sup.a和R.sup.a是C.sub.1-C.sub.6烷基或氢，最多3个烷基基团，m为1、2或3，Y为两个氢或氧）；但当E表示亚甲基时，R.sup.3是C.sub.1-C.sub.6烷基或R.sup.3和R.sup.4共同表示式(IV)的一个组。该方法包括将式为##STR2##的酸与式为##STR3##的胺反应。
• Analgesic compounds, their preparation, and pharmaceutical compositions
  申请人：Sankyo Company, Limited

  公开号：US05270327A1

  公开（公告）日：1993-12-14

  Analgesic compounds of the formula (I): ##STR1## in which, R.sup.1 R.sup.2 each represents hydrogen or C.sub.1 -C.sub.6 alkyl, or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a 5-6-membered N-heterocyclic ring optionally having a further O, N, or S heteroatom; E represents methylene; ring A is an unsubstituted or substituted benzene or naphthalene; R.sup.3 and R.sup.4 together represent a group of formula (IV): --(CR.sup.a R.sup.a).sub.m --C(=Y)-- (IV) wherein R.sup.a and R.sup.a is C.sub.1 -C.sub.6 alkyl or hydrogen with up to a maximum of 3 alkyl groups, m is 1, 2, or 3, and Y is two hydrogens or oxygens.

  式(I)的镇痛化合物：##STR1## 其中，R.sup.1和R.sup.2各代表氢或C.sub.1-C.sub.6烷基，或R.sup.1和R.sup.2连同它们所连接的氮原子形成一个5-6元杂环，可选地具有另外的O，N或S杂原子；E代表亚甲基；环A是未取代或取代的苯或萘；R.sup.3和R.sup.4共同表示公式(IV)的一个基团：--(CR.sup.a R.sup.a).sub.m --C(=Y)-- (IV)，其中R.sup.a和R.sup.a是C.sub.1-C.sub.6烷基或氢，最多有3个烷基基团，m为1、2或3，Y为两个氢或氧原子。
• Analgesic carboxylic acid amide derivatives
  申请人：Sankyo Company Limited

  公开号：EP0356247A1

  公开（公告）日：1990-02-28

  Analgesic compounds are of the general formula (I): in which, R¹ and R² each represents hydrogen or C₁-C₆ alkyl, or R¹ and R² together with the nitrogen atom to which they are attached form a heterocycle; E represents methylene, sulphur, oxygen or imino group optionally substituted with C₁-C₆ alkyl or aralkyl; ring A is aryl or heteroaryl ring, optionally substituted; R³ is hydrogen or C₁-C₆ alkyl and R⁴ is hydrogen or R³ and R⁴ together represent a group of formula (IV): -(CRaRa)m-C(=Y)-      (IV) (wherein Ra and Ra is C₁-C₆ alkyl or hydrogen, up to a maximum of 3 alkyl groups, m is 1, 2, or 3, and Y is two hydrogens or oxygen); provided that when E represents a methylene group, then R³ is a C₁-C₆ alkyl group or R³ and R⁴ together represent a group of the formula (IV).

  镇痛化合物的通式为(I)： 其中，R¹ 和 R² 各自代表氢或 C₁-C₆烷基，或 R¹ 和 R² 与它们所连接的氮原子一起形成杂环；E 代表亚甲基、硫、氧或亚氨基，可选择被 C₁-C₆ 烷基或芳烷基取代；环 A 是任选被取代的芳基或杂芳基环；R³ 是氢或 C₁-C₆ 烷基，R⁴ 是氢或 R³ 和 R⁴ 共同代表式 (IV) 的基团： -(CRaRa)m-C(=Y)-(IV) (其中 Ra 和 Ra 是 C₁-C₆ 烷基或氢，最多 3 个烷基，m 是 1、2 或 3，Y 是两个氢或氧)；条件是当 E 代表亚甲基时，R³ 是 C₁-C₆ 烷基或 R³ 和 R⁴ 共同代表式(IV)的基团。
• EP0356247B1
  申请人：——

  公开号：EP0356247B1

  公开（公告）日：1993-03-17